Analyst consensus rating
Ernexa Therapeutics Analyst Rating: Strong Buy
ERNA is rated Strong Buy by 1 analysts with a $30.00 target. As of 2026-08-16.
Direct answer
Ernexa Therapeutics's consensus rating is Strong Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $30.00.
Forecast evidence checked August 16, 2026.
Get free Ernexa Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.27
- Average price target
- $30.00
- High price target
- $30.00
- Low price target
- $30.00
- Low target gap
- +602.6%
- Target upside
- +602.6%
- High target gap
- +602.6%
- Target range width
- 0%
- Consensus rating
- Strong Buy
- Analysts
- 1
- Evidence date
- August 16, 2026
- Valid through
- August 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ernexa Therapeutics?
Ernexa Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $30.00.
How far are Ernexa Therapeutics's low and high targets from the recorded price?
The low target implies +602.6%, while the high target implies +602.6%.
How many analysts are included in Ernexa Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is Ernexa Therapeutics's target upside or downside calculated?
The average target of $30.00 is divided by the recorded price of $4.27, then one is subtracted to produce +602.6%. This does not guarantee a future return.
When was Ernexa Therapeutics's analyst forecast verified?
The data was verified on 2026-08-16. The dataset is valid through 2026-08-23.